Project Description


At a glance

Ayana Pharma is uniquely positioned to expand the uses and efficacy of the lipid-based cytotoxic drug’s well-established clinical profile. Invented by Prof. Yechezkel Barenholtz from the Hebrew University who is also the co-founder of Ayana Pharma.

Market Potential

Ayana Pharma expects to reach substantial revenues from commercializing its product globally.

Company Highlights

A lipid-based cytotoxic agent reaching its final clinical development.

Key Shareholders

Integra Holdings, Prof. Yechezkel Barenholtz, the Teachers & Kindergarten Funds and Michael Ilan Investment group.


Ayana Pharma completed fundraising to support product development and FDA filing.

More Companies